The Federal Government has granted ₦24 billion in tax waivers to pharmaceutical manufacturers between 2025 and 2026 as part of efforts to expand local drug production and reduce dependence on imported medicines.
Coordinating Minister of Health and Social Welfare, Muhammad Pate, disclosed this at the 2026 Nigeria Health Sector Joint Annual Review in Abuja, saying the incentives were introduced under a presidential executive order signed in 2024.
Pate said the government had secured 12 technology-transfer agreements and attracted a prospective investment pipeline worth more than $5 billion.
He added that 10 factories and manufacturing lines had been commissioned under the healthcare industrialisation programme, including six in 2026. The facilities produce medicines, rapid diagnostic tests, long-lasting insecticidal nets and medical oxygen.
According to the minister, the priority is to convert prospective investments into operational businesses capable of supplying affordable and quality healthcare products while creating employment opportunities.
Zebra News reports that Minister of State for Health and Social Welfare, Iziaq Salako, said locally manufactured medicines accounted for 50 per cent of Nigeria’s pharmaceutical market in 2026, compared with 30 per cent in 2023.
He also disclosed that the number of active local pharmaceutical companies had increased by about 10 per cent.
Salako said the government was targeting at least 70 per cent local production of essential healthcare products by 2030, while 87 manufacturers were benefiting from zero tariffs on selected pharmaceutical machinery, active pharmaceutical ingredients and production materials.
Pate also said the government was working to operationalise Medipool, a group purchasing organisation designed to consolidate public-sector demand for medicines and healthcare supplies, making demand more predictable for local manufacturers.
President Bola Tinubu signed the executive order in July 2024, providing relief from tariffs, excise duties and value-added tax on specified pharmaceutical machinery, equipment and raw materials.
Salako said expanding local production into vaccines, diagnostic tests and active pharmaceutical ingredients would be crucial to strengthening Nigeria’s healthcare supply chain.

